UBS Group
AVXL icon

UBS Group’s Anavex Life Sciences AVXL Stock Holding History

UBS Group’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-20,000
Closed -$186K – 9288
2023
Q4 		$186K Buy
+20,000
New +$138K ﹤0.01% 5819
2019
Q1 		– Sell
-9,900
Closed -$15K – 7719
2018
Q4 		$15K Hold
9,900
– – ﹤0.01% 6982
2018
Q3 		$27K Hold
9,900
– – ﹤0.01% 6610
2018
Q2 		$26K Buy
+9,900
New +$27.7K ﹤0.01% 6501

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group's AVXL Position: Q2 2026 in Review

UBS Group increased its Anavex Life Sciences (AVXL) stake by 8.8% in Q2 2026, buying an estimated $149K and bringing the position to 620,374 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #5310.

UBS Group first reported a position in AVXL in Q4 2015 and has held it in 43 quarters since. The position peaked at $5.22M in Q1 2025. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • UBS Group held 620,374 shares of Anavex Life Sciences worth $1.61M as of Q2 2026.
  • UBS Group bought 50,418 Anavex Life Sciences shares in Q2 2026, an estimated $149K.
  • Anavex Life Sciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5310 holding.
  • UBS Group first reported a position in Anavex Life Sciences in Q4 2015 and has held it in 43 quarters since.
  • UBS Group's Anavex Life Sciences position peaked at $5.22M in Q1 2025.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.